Everything published about Semaglutide: mechanism, research areas, results, regimens, risks, comparisons — plus the dated Vietnam price and ordering rules.
| Format | Price (index Nov 2, 2026) | Delivery |
|---|---|---|
| 5 mg | from 1 100 000 ₫ | Da Nang ~30 min · Vietnam 1–2 days |
Semaglutide is a long-acting GLP-1 analogue that influences appetite, fullness and food intake. Its once-weekly injectable formulations have made it a familiar reference point in weight management.
Licensed formulations are used for type 2 diabetes and chronic weight management, with additional indications in specific eligible populations.
A well-established GLP-1 medicine in licensed formulations, with strong clinical evidence for appetite regulation, weight management and glucose control.
In a 68-week weight-management trial, adults without diabetes lost an average of 14.9% at 68 weeks, versus 2.4% with placebo, with lifestyle support in both groups. A separate cardiovascular-outcomes trial also found fewer major cardiovascular events in an eligible high-risk population.
Once-weekly subcutaneous schedule studied for weight management: Weeks 1–4: 0.25 mg weekly Weeks 5–8: 0.5 mg weekly Weeks 9–12: 1 mg weekly Weeks 13–16: 1.7 mg weekly From week 17: target 2.4 mg weekly The trial lasted 68 weeks. Weight-management treatment is generally ongoing rather than a short fixed cycle.
Nausea, vomiting, diarrhoea and constipation are common. Important precautions include pancreatitis, gallbladder disease, medullary thyroid cancer/MEN2 and hypoglycaemia with insulin or sulfonylureas. Weight-management use stops in pregnancy; the label specifies stopping at least two months before a planned pregnancy.
Semaglutide works through GLP-1, while tirzepatide combines GLP-1 and GIP. Both have extensive weight-management research, with different receptor profiles.
from 1 100 000 ₫ for 5 mg (index Nov 2, 2026); final total confirmed in writing before payment.
No: research material, not a prescription drug; no medical claims.